We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest close session, Merck (MRK - Free Report) was up +1.31% at $115.68. The stock's change was more than the S&P 500's daily gain of 1.15%. At the same time, the Dow added 1.38%, and the tech-heavy Nasdaq gained 1.38%.
Coming into today, shares of the pharmaceutical company had lost 6.61% in the past month. In that same time, the Medical sector lost 8.2%, while the S&P 500 lost 5.69%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $5.47 per share and revenue of $66.68 billion. These results would represent year-over-year changes of -39.09% and +2.57%, respectively.
It is also important to note the recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.18% rise in the Zacks Consensus EPS estimate. Merck is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Merck is currently trading at a Forward P/E ratio of 20.89. This expresses a premium compared to the average Forward P/E of 14.11 of its industry.
We can additionally observe that MRK currently boasts a PEG ratio of 2.08. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 2.08 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 176, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
In the latest close session, Merck (MRK - Free Report) was up +1.31% at $115.68. The stock's change was more than the S&P 500's daily gain of 1.15%. At the same time, the Dow added 1.38%, and the tech-heavy Nasdaq gained 1.38%.
Coming into today, shares of the pharmaceutical company had lost 6.61% in the past month. In that same time, the Medical sector lost 8.2%, while the S&P 500 lost 5.69%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $5.47 per share and revenue of $66.68 billion. These results would represent year-over-year changes of -39.09% and +2.57%, respectively.
It is also important to note the recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.18% rise in the Zacks Consensus EPS estimate. Merck is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Merck is currently trading at a Forward P/E ratio of 20.89. This expresses a premium compared to the average Forward P/E of 14.11 of its industry.
We can additionally observe that MRK currently boasts a PEG ratio of 2.08. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 2.08 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 176, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.